Nanobiosym Pilot: Optimization and Evaluation of Gene-RADAR® Nanotech platform Point-Of-Care HIV Diagnostic Device Prevention of Mother-To-Child Transmission in Rwanda

Organization: 
Nanobiosym, Inc
Organization Location: 
Cambridge, MA, USA

In Rwanda, 90% of all cases of infant and child HIV infections occur through mother-to-child transmission (MTCT). Studies led by Dr. Katherine Luzuriaga demonstrated that early antiretroviral therapy (ART) markedly reduces HIV-related mortality in infants. However, in resource limited settings, the lack of molecular diagnostic methods for early infant diagnosis prevents the timely application of lifesaving HIV therapy. The Nanobiosym Gene-RADAR ® nanotechnology platform addresses this critical gap by enabling rapid, accurate, mobile, gold-standard viral load monitoring at the point-of-care at an affordable cost. In collaboration with Partners in Health in Rwanda, Nanobiosym will deliver, pilot, and evaluate Gene-RADAR ®, to provide early detection of HIV and demonstrate the eradication of MTCT through its mobile health applications. In combination with timely ART this platform could save thousands of young Rwandan lives. Nanobiosym's Gene-RADAR ® nanodiagnostic enables real-time analysis of genetic fingerprints contained in a drop of blood or saliva, as well as the first-of-its-kind capability to quantify the HIV viral load in a field setting at an affordable price. Its ability to measure viral load during gestation, delivery, and post-partum in mothers and infants will enable earlier detection and customization of ART in real time, eliminating the need for costly and resource intensive lab infrastructure. By calibrating ART and routinely monitoring viral load, Gene-RADAR®  will enable doctors in the developing world to screen, customize, and adjust the dosing regimen for maximum impact on MTCT.  

See video